No Data
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 Loss per Share (Vs US$1.01 Loss in 3Q 2023)
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
Crinetics Pharmaceuticals: Promising Future With Innovative Drug Developments and Strong Financial Position
Crinetics Pharmaceuticals Analyst Ratings
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71